HTG, Inc., a provider of novel array-based gene expression assay technology and services for the life sciences industry, today announced it has named Jonathan M. Sheridan to the position of Vice President of Commercial Operations. In addition to Sheridan’s appointment, the company also announced the opening of a second office location in Madison, Wisconsin which Sheridan will manage.
In his new role, Sheridan will be responsible for forming new business partnerships with pharmaceutical and life sciences companies, establishing research agreements with academic institutions, and managing the global commercial sales and marketing teams.
“We are delighted to welcome Jonathan to HTG’s executive management team. With more than 20 years of biotech experience, he will play an instrumental role as we move to expand our commercial operations. Building a best-in-class commercial organization is a priority for HTG, and we are thrilled to open our second US-based location in Madison,” said Tim (TJ) Johnson, president and chief executive officer, HTG.
“It’s a privilege to join the HTG management team. With my relevant background and industry experience this was an ideal fit,” said Jonathan Sheridan. “I am looking forward to contributing to the company’s success in my new capacity.”
Prior to HTG, Sheridan was Director of Sales and Corporate Development for EPICENTRE® Biotechnologies, a manufacturer of molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Before joining EPICENTRE, he was a genomics and proteomics regional product line leader for PerkinElmer Life and Analytical Sciences. Sheridan also held positions with PerkinElmer Cetus, Beckman Coulter, LiCor and Monsanto. Sheridan earned a B.S. in chemistry from Lambuth University, Jackson, Tenn.
The new office is located at 8025 Excelsior Drive in Madison, Wisconsin.
HTG’s qNPA technology is used to carry out quantitative multiplexed, gene-based drug discovery programs, including target validation, HTS lead optimization, metabolism, toxicology and clinical development. HTG’s platform allows scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification. The platform provides high-quality quantitative test results enabling clients to compress drug discovery and development program timelines, increase program success and reduce costs.
About HTG
Privately-held HTG is headquartered in Tucson, Arizona. Investors in the company include Solstice Capital, Valley Ventures, Merck Capital Ventures, Village Ventures and Arcturus Capital